

# PULMOTECT

## Pulmotect Receives First Tranche of \$8.9 Million from The State of Texas

*Funding from the Cancer Prevention and Research Institute of Texas will support development for Phase 2 Anti-Viral Trial and further development of PUL-042*

HOUSTON, TEXAS , UNITED STATES, December 1, 2023 -- Houston, TX [Pulmotect, Inc.](#), a privately held clinical-stage biotechnology company, today announced that it has received the initial \$1.26 million of an \$8.9 million Product Development Research grant by the [Cancer Prevention and Research Institute of Texas](#) (CPRIT) to fund the continued development and the Company's lead asset PUL-042 in a Phase 2 Anti-Viral Trial.

“We are appreciative of this funding following the extensive diligence process conducted by CPRIT and we are eager to conduct this planned Phase 2 Anti-Viral trial to bring much needed help to the cancer community” said Dr. Colin Broom, CEO of Pulmotect.

The trial is entitled “A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients with Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) with Documented Viral Infections with Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)”. This trial builds upon the successful Phase 2 trials conducted against SARS-CoV-2. It has been demonstrated that PUL-042 has the potential to prevent upper respiratory infection from progressing to pneumonia. Illustrating that same outcome in the highly vulnerable cancer patient populations would be significant and could save countless lives.

About the Cancer Prevention & Research Institute of Texas (CPRIT)

CPRIT was created by the Texas Legislature and approved by a statewide vote in 2007 to lead the Lone Star State's fight against cancer. In 2019, Texas voters again voted overwhelmingly to support CPRIT with an additional \$3 billion for a total \$6 billion investment in cancer research and prevention. To date, the agency has awarded over \$3 billion in grants to Texas research institutions and organizations through its academic research, prevention, and product development research programs. CPRIT has also recruited more than 302 distinguished researchers to Texas, supported the establishment, expansion, or relocation of 62 companies to Texas, and supported more than 9.3 million prevention services reaching all 254 counties in Texas. Learn more at [cprit.texas.gov](http://cprit.texas.gov).

#### About PUL-042

PUL-042, a first-in-class, synergistic combination of two toll-like receptor agonists, activates the lungs' surface innate immune system to inhibit and kill a wide range of respiratory pathogens. As microbes, including viruses, land on the epithelial cells of the lung lining, they are destroyed on contact by antimicrobial peptides and reactive oxygen species (ROS) that are released by epithelial cells. Activation of the innate immune system also triggers a response from the adaptive immune system. PUL-042 has demonstrated protection against a broad range of respiratory pathogens in pre-clinical models, including the coronaviruses that cause MERS and SARS. With robust pre-clinical protection shown against multiple pathogens, even in models with immunocompromised animals, and favorable tolerability demonstrated in clinical trials to date, PUL-042 could offer a broad-spectrum therapy for responding to epidemics and pandemics including current and future SARS-CoV-2 variants and has potential use for multiple other indications.

#### About Pulmotect

Pulmotect has an immunomodulatory platform technology and is developing PUL-042, a clinical-stage, first-in-class, inhaled, immunomodulatory agent. A synergistic agonist that amplifies the innate immune defenses of the lung epithelial mucosa to provide broad-spectrum, pathogen-agnostic protection against respiratory infections. Invented at UT MD Anderson Cancer Center/Texas A&M University, PUL-042 has patents issued in 28 countries, both as a stand-alone composition of matter product and in combination with antivirals. For more information, visit [www.pulmotect.com](http://www.pulmotect.com).

#### Pulmotect Investor Relations/Questions:

Brenton Scott  
Pulmotect, Inc.  
+1 713-579-9226